Treatment Evolution after COPD Diagnosis in the UK Primary Care Setting

Keele E. Wurst1*, Yogesh Suresh Punekar2, Amit Shukla3

1 Worldwide Epidemiology, GlaxoSmithKline R&D, Research Triangle Park, North Carolina, United States of America, 2 Global Health Outcomes, GlaxoSmithKline R&D, Uxbridge, Middlesex, United Kingdom, 3 Worldwide Epidemiology, GlaxoSmithKline R&D, Upper Providence, Pennsylvania, United States of America

Abstract

Rationale: To assess the treatment progression during the 24 months following a formal diagnosis of chronic obstructive pulmonary disease (COPD) in the UK primary care setting.

Methods: A retrospective cohort of newly diagnosed COPD patients was identified in the Clinical Practice Research Datalink (CPRD) from 1/1/2008 until 31/12/2009. Maintenance therapy prescribed within the first 3 months of diagnosis and in the subsequent 3-month intervals for 24 months were analyzed. Treatment classes included long-acting β2-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), inhaled corticosteroids (ICSs), and respective combinations. At each 3-month interval, discontinuation, switching, addition, and stepping down patterns were analyzed cumulatively for the first 12 months and over the 24-month of follow-up.

Results: A total of 3199 patients with at least one prescription of a maintenance therapy at baseline and during 4th-6th month interval were included in the analysis. At diagnosis (0–3 months), the most frequently prescribed maintenance therapy was LABA+ICS (43%), followed by LAMA (24%) and LABA+LAMA+ICS (23%). Nearly half the patients (LABA-50%, LAMA-43%) starting on a monobronchodilator had additions to their treatment in 24 months. Compared to other medications, patients starting on a LAMA were most likely to escalate to triple therapy in 24 months. Nearly one-fourth of the patients prescribed triple therapy at baseline stepped down to LABA+ICS (25%) or LAMA (31%) within 24 months.

Conclusion: Disease progression is evident over the 24 months after COPD diagnosis, as more patients were prescribed additional maintenance therapy in the 24-month period compared to baseline. The changes in therapy suggest that it is difficult to achieve a consistently improved COPD disease state.

Introduction

Chronic obstructive pulmonary disease (COPD) is “a preventable and treatable disease characterized by airflow limitation that is not fully reversible” [1]. It remains a major healthcare problem, and various guidelines have been created to aid in effective management of this disease [1–4]. International guidelines such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy and local guidelines such as the National Institute for Health and Care Excellence (NICE) provide guidance to physicians in treating COPD [1].

Once COPD is diagnosed and its severity is established, pharmacological treatment aims to reduce symptoms and exacerbations [2,3]. Short-acting β2-agonists (SABAs) are used on an as-needed basis for symptomatic relief in early stages. As COPD is a progressive condition, daily maintenance drugs are usually needed. GOLD and NICE guidelines suggest that bronchodilators such as β2-agonists and antimuscarinics form the mainstay of therapy [1,2]. Changes in forced expiratory volume in 1 second (FEV1) following bronchodilator therapy can be small; however, the accompanying larger change in lung volume contributes toward reduction in perceived breathlessness [3]. Long-acting β2-agonists (LABAs) or long-acting muscarinic antagonists (LAMAs) are also used to reduce the number and severity of exacerbations [6]. Combination therapy produces a greater change in spirometry and symptoms in comparison with monotherapy [7]. A combination of LABA and LAMA is prescribed if symptoms persist even after individual bronchodilator monotherapy. Inhaled corticosteroids (ICSs) are added as anti-inflammatory agents to reduce the rate of exacerbation in patients with severe disease [2,8,9]. NICE guidelines in the UK indicate a stepwise progression from bronchodilator monotherapy to a combination therapy based on the level of post-bronchodilator FEV1 percent predicted. For patients with FEV1 ≥ 50%, a LAMA or a LABA is recommended as the initial choice. If the FEV1 is <50%, the treatment choice is between a LAMA or LABA+ICS. Patients starting on LAMA or...
Table 1. Patient disposition and demographic characteristics.

| Patient Variable, n (%) | Total COPD Cohort |
|-------------------------|-------------------|
| All COPD                | 3199 (100.0)      |
| Age, mean (SD)          | 67.29 (10.7)      |
| Female                  | 1489 (46.55)      |
| Smoking status - Current smoker | 1155 (36.11) |
| Smoking status - Former smoker | 480 (15.00) |
| BMI, kg/m²              | 27.05 (6.11)      |
| Charlson Score Prior    | 532 (16.63)       |
| Acute myocardial infarction | 271 (8.47)     |
| Congestive heart disease| 203 (6.35)        |
| Cerebrovascular disease | 211 (6.60)        |
| Depression              | 416 (13.00)       |
| Anxiety                 | 492 (15.38)       |
| Asthma                  | 1417 (44.30)      |
| Cancer                  | 392 (12.25)       |
| Diabetes                | 447 (13.97)       |
| Diabetes with complications | 93 (2.91)       |
| Severity COPD GOLD 1    | 448 (14.00)       |
| Severity COPD GOLD 2    | 1557 (48.67)      |
| Severity COPD GOLD 3    | 925 (28.92)       |
| Severity COPD GOLD 4    | 185 (5.78)        |
| MRC 1                   | 394 (12.32)       |
| MRC 2                   | 870 (27.20)       |
| MRC 3                   | 558 (17.44)       |
| MRC 4                   | 237 (7.41)        |
| MRC 5                   | 42 (1.31)         |

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease stage of airflow limitation; MRC, Medical Research Council dyspnea scale; SD, standard deviation.

Patient characteristics such as age, gender, body mass index (BMI), smoking status, available Medical Research Council (MRC) dyspnea scale score, and prior diagnosed and/or treated comorbid conditions (according to the Charlson index) [14] any time in the patient record were assessed at and prior to the cohort entry date. COPD prescriptions were evaluated at cohort entry date and every 3 months thereafter for a total follow-up duration of 24 months. The 3-month intervals included were 0–3 (baseline), 4–6, 7–9, 10–12, 13–15, 16–18, 19–21, and 22–24 following the cohort entry date. Treatment classes included LABAs and LAMAs alone, in combination (LABA+LAMA), and with an ICS (LABA+ICS, LAMA+ICS, and LABA+LAMA+ICS). All multiple therapies, either in combination or as separate inhalers, were required to be prescribed on the same day or within a 30-day period. Each medication category was mutually exclusive, irrespective of the use of short-acting bronchodilators (SABDs). The first maintenance prescription for COPD (either single or combination within 30 days) in each 3-month period was recorded as the therapy for that period.

In order to assess the progression through individual maintenance therapy, patients prescribed one of the following six index therapies at baseline and at each 3-month interval were included: LABA, LAMA, LABA+LAMA, LABA+ICS, LAMA+ICS, and LABA+LAMA+ICS. ICS as a standalone treatment was excluded, as ICS is not licensed as monotherapy for COPD. Patients were categorized into a baseline treatment class based on their first prescription in the 0- to 3-month interval. Patients were considered to continue on this index therapy if they were prescribed the same therapy in subsequent 3-month time intervals. Patterns of first change in treatment (addition, discontinuation, step down, and switch from index therapy) were analyzed at each time interval and cumulatively in the first (1–12 months) and second year (0–24 months). Patients with any change in therapy were excluded in subsequent intervals, thereby restricting the analysis to patients continuing on index therapy, while recording their first change.

In addition, the time to first prescription of triple therapy by index therapy among all newly diagnosed patients was evaluated using a Kaplan–Meier curve. Exploratory analysis was performed using Cox proportional hazards models by excluding asthma and adjusting for factors associated with progression to triple therapy.
Patients (n = 3199) prescribed maintenance therapy at baseline and 3–6 months excluding patients with no treatment, SABD alone, ICS, and others. Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.

doi:10.1371/journal.pone.0105296.g001

To be included in analysis, patients had to receive a prescription at each 3-month interval. Triple, LABA+LAMA+ICS. Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.

doi:10.1371/journal.pone.0105296.g002
Results

Patient disposition and demographic characteristics

Among the cohort of 7881 newly diagnosed patients with COPD, 3925 (50%) were prescribed maintenance therapy during the baseline period (0–3 months after diagnosis). Of the 3925 patients, 80% (n = 3199) were prescribed a maintenance therapy at baseline and during the 4–6 month interval and were included in this analysis. These patients had a mean (SD) age of 67 (11) years. The cohort consisted of 47% women, 15% former smokers, and 36% current smokers. Additionally, 97% and 66% of patients had an available stage of lung function and MRC dyspnea scale score, respectively (Table 1). The demographic distribution did not differ substantially from the overall newly diagnosed cohort apart from the stages of lung function and MRC score, where a higher proportion of patients prescribed maintenance therapy (n = 3199) had percent-predicted FEV1,50% (35% vs 27%) and MRC score ≥3 (26% vs 21%).

Treatments at baseline

The frequency distribution of each type of prescribed therapy following a new diagnosis of COPD is shown in Figure 1. At diagnosis (0–3 months), the most frequently prescribed maintenance therapy was LABA+ICS (43%), followed by LAMA (24%) and LABA+LAMA+ICS (23%). The distribution of maintenance therapy was similar between patients prescribed a maintenance therapy at baseline (0–3 months, n = 3925) and those included in this analysis (n = 3199); data not shown.

Changes in therapy over 24 months

Continuing on the same medication. Approximately one-quarter of the cohort was not prescribed their initial therapy again in the first 4–6 months following diagnosis; half of the cohort was not prescribed their initial therapy again after 12 months; and approximately three-quarters of the cohort was not prescribed their initial therapy again after 2 years (Figure 2).

Patients on LABA+ICS combination demonstrated highest continuation, with 60% at interval 4 (10–12 months), and 33% at interval 8 (22–24 months) continuing on their index therapy. Patients on LABA and LAMA monotherapies had comparable continuation with 42% and 44% patients on the index treatment at interval 4 and 21% and 22% on index treatment at interval 8, respectively. The proportion of patients remaining on their initial therapy at the end of 24 months varied between initial medications prescribed. The proportions ranged from 9% for LAMA+ICS to 35% for LABA+ICS and about 25% for most other therapies (Figure 3). There were also a number of patients within each therapy group who were not prescribed a COPD maintenance therapy in the 3-month period following their initial prescription or first change in therapy (Figure 3).

Additions. Table 2 shows that a majority of additions occurred within the first 12 months of diagnosis. Among patients starting on a LABA or a LAMA therapy respectively, ICS (23% at 12 months, 26% at 24 months) and ICS+LABA (27% at 12 months and 33% at 24 months) were the most common additions within 12 and 24 months of follow-up. Other major additions within first 12 months included addition of ICS to LABA+LAMA starters (21% at 12 months, 29% at 24 months) and addition of a LAMA to ICS+LABA starters (17% at 12 months and 24% at 24 months) (Table 2).

Switching or stepping down therapy. Few patients were prescribed another class of maintenance therapy within 24 months of diagnosis. Similar to additions, a majority of switches occurred within the 12 months of diagnosis (Table 3). A small percentage of patients switched from LABA to LAMA and from LAMA to LABA (Table 3).
### Table 2. Proportions of patients adding to medication.

| Treatment Class | N* | LABA | LAMA | LABA+ LAMA | LABA + ICS | LAMA + ICS | LABA+ LAMA+ ICS |
|-----------------|----|------|------|-----------|-----------|-----------|----------------|
| LABA 0–12 months | 142 | -    |      | 8.9%      | 23.2%     | 5.6%      |                |
| 0–24 months     | 142 | -    |      | 14.8%     | 28.9%     | 6.3%      |                |
| LAMA 0–12 months | 773 | -    |      | 3.0%      | 3.9%      | 26.8%     |                |
| 0–24 months     | 773 | -    |      | 4.5%      | 5.2%      | 33.2%     |                |
| LABA+LAMA 0–12 months | 47 | -    |      | -         | -         | -         |                |
| 0–24 months     | 47  | -    |      | -         | -         | -         |                |
| LABA+ICS 0–12 months | 1387 | -    |      | -         | -         | -         |                 |
| 0–24 months     | 1387 | -    |      | -         | -         | -         |                 |
| LAMA+ICS 0–12 months | 90  |      |      | -         | -         | -         |                |
| 0–24 months     | 90   |      |      | -         | -         | -         |                |

*Number of patients starting/remaining on treatment at the beginning of the year.

Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
doi:10.1371/journal.pone.0105296.t002

### Table 3. Proportions of patients switching to another medication or stepping down treatment.

| Treatment Class | N* | LABA | LAMA | LABA+ LAMA | LABA + ICS | LAMA + ICS | LABA+ LAMA+ ICS |
|-----------------|----|------|------|-----------|-----------|-----------|----------------|
| LABA 0–12 months | 142 | -    |      | 4.2%      | NA        | NA        | 0.0%          |
| 0–24 months     | 142 | -    |      | 4.2%      | NA        | NA        | 0.0%          |
| LAMA 0–12 months | 773 | 0.0% | -    | NA        | 7.6%      | NA        | NA            |
| 0–24 months     | 773 | 0.0% | -    | NA        | 9.4%      | NA        | NA            |
| LABA+LAMA 0–12 months | 47 | 12.8% | 17.0% | -         | 12.8%     | 4.3%      | NA            |
| 0–24 months     | 47  | 12.8% | 19.1% | -         | 12.8%     | 4.3%      | NA            |
| LABA+ICS 0–12 months | 1387 | 2.2% | 3.7% | 0.0%      | -         | 0.0%      | NA            |
| 0–24 months     | 1387 | 2.6% | 4.8% | 0.0%      | -         | 0.0%      | NA            |
| LAMA+ICS 0–12 months | 90 | 0.0% | 44.4% | 0.0%      | 6.7%      | -         | NA            |
| 0–24 months     | 90   | 0.0% | 47.8% | 0.0%      | 7.8%      | -         | NA            |
| LABA+LAMA+ ICS 0–12 months | 760 | 0.3% | 23.0% | 0.4%      | 19.2%     | 0.9%      | -             |
| 0–24 months     | 760  | 0.3% | 31.3% | 0.7%      | 24.5%     | 1.3%      | -             |

*To be included in analysis, patients had to receive a prescription at each 3-month interval.

Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
doi:10.1371/journal.pone.0105296.t003
Patients prescribed more than one maintenance medication in combination were included in the stepped down therapy analysis. Among patients starting on dual therapies, majority of step downs occurred in patients starting on LAMA+ICS therapy with 44% stepping down to LAMA monotherapy within first 12 months. Several patients starting on LABA+LAMA combination also stepped down to a LABA (13%) or a LAMA (17%) monotherapy within 12 months. Majority of patients prescribed triple therapy at baseline stepped down to LABA+ICS (19%) or LAMA (23%) during the 24-month follow-up (Table 3).

Progression to triple therapy. Results from the Kaplan-Meier survival analysis showed that the proportion of patients that progressed to triple therapy varied depending on the initial medication prescribed (Table 4). At 1 year, only 7% of patients who had not been prescribed COPD therapy initially had progressed to triple therapy. Among those prescribed LABD or an ICS combination initially, 32% and 25% of the patients, respectively, had progressed to triple therapy at 1 year, and 46% and 39% of the patients, respectively, had progressed to triple therapy at 2 years. When asthma was excluded and factors associated with progression to triple therapy (airflow limitation, underweight BMI, and suspected exacerbations) were adjusted for, the same trend was observed, i.e., patients who received LABD or an ICS combination initially were prescribed triple therapy at a faster rate than those with other initial therapies (data not shown).

### Table 4. Percent of patients that progressed to triple therapy within 2 years by index treatment prescribed.

| Initial prescription at new COPD diagnosis, n | Progressed to triple therapy at 365 days, n (%) | Progressed to triple therapy at 730 days, n (%) |
|---------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| SABD, n = 1804                              | 174 (10)                                      | 353 (20)                                      |
| LABD (LAMA or LABA), n = 1232               | 397 (32)                                      | 568 (46)                                      |
| ICS, n = 724                                | 78 (11)                                       | 132 (18)                                      |
| ICS combination (LABA+ICS or LAMA+ICS), n = 1856 | 461 (25)                                      | 723 (39)                                      |
| No treatment, n = 1181                      | 88 (7)                                        | 182 (15)                                      |

Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LABD, long-acting bronchodilator; LAMA, long-acting muscarinic antagonist; SABD, short-acting bronchodilator.

doi:10.1371/journal.pone.0105296.t004

Discussion

In this study, we evaluated the treatment paradigm evolving over 24 months after the first diagnosis of COPD in the UK general practice. Maximum variability in treatment was observed within the first 6 months, with approximately 15% to 49% of patients changing their initial therapy. Beyond this period, patients gradually stabilized on their respective treatments, with limited changes over the next 18 months of the follow-up. Majority of changes beyond 6 months included addition of treatments with limited switches. In addition, the index treatment was discontinued for most patients within the 24 months of diagnosis irrespective of the treatment class. This gradual yet significant change in therapy may indicate the difficulty in achieving a stable disease state in a progressive disease such as COPD. Thus, this observed change from initial therapy, with addition or switching, may suggest suboptimal disease control.

The results of this study are consistent with other studies that examined treatment patterns in COPD. Overall retention of treatment was low across all medications, although differences were observed among different treatment classes. In a study using the Ontario Drug Benefit Program database, Cramer et al demonstrated that 15–63% of patients continued on their index drug for more than six months [15]. Corresponding estimate in our study was 40–70%. Our results were also consistent with Cramer et al at 12 and 18 months [15].

The Cramer et al study found that patients stayed on tiotropium treatment significantly longer than other daily medications. In contrast, the treatment class with maximum retention in our study was LABA+ICS. The patients in the current study could represent COPD patients with concomitant yet undiagnosed asthma as 44% of the patients prescribed LABA+ICS in the total cohort had at least one asthma diagnosis in their record. These patients may also have had exacerbations in their previous history and received benefit from the ICS.

Guidelines suggest adding an ICS as anti-inflammatory agents to reduce the rate of exacerbation in patients with severe disease [2,8,9]. Our analysis showed that within 24 months, ICS as a single inhaler or LABA+ICS combination inhaler, was added for 35% and 38% of patients starting on a LABA and a LAMA monotherapy, respectively. This indicates that a substantial number of patients on bronchodilator monotherapy may require an ICS to possibly manage their risk of exacerbations. Similarly, a substantial number of patients starting on a LABA or a LAMA also added a second bronchodilator (with or without an ICS) within 24 months of COPD diagnosis. This may also suggest the progressive nature of COPD requiring additional pharmacotherapy to maintain lung capacity, though the data only allow generation of hypotheses due to lack of physician recording of the rationale behind medication changes.

Many patients starting on a long-acting bronchodilator (LAMA or LABA) or an ICS combination that includes a long-acting bronchodilator received a prescription for triple therapy by the end of the 2-year study period. This finding was observed with two different analyses: when patients were analyzed from their first maintenance therapy until first change in prescription, and when patients were followed up throughout the study period. Thus, the results suggest that COPD treatment evolution is progressive and patients probably need more than one maintenance medication to achieve symptom relief and/or prevent exacerbations.

Stepping down therapy may be reflective of prescriptions of multiple inhalers used intermittently. Among triple therapy initiators who stepped down during the follow-up period, majority of patients stepped down to a LAMA or an LABA+ICS combination. This study only addressed first change in therapy and perhaps these patients may have been prescribed triple therapy again at a later date.

Study limitations included the fact that GPRD only captures diseases diagnosed in the primary care setting. Also, there may be a possibility of misclassification of drug exposure because the GPRD provides information on prescribed rather than dispensed...
medications. However, audits of electronic medical records in the UK have shown a relatively high concordance of dispensing to prescription (99.7% of prescriptions tracked were recorded by the electronic patient record during a month) [16]. Only patients alive for 24 months were included in the analysis thus the findings may not be representative of most severe COPD patients.

**Conclusion**

Challenges in optimally managing the condition were evident over the 24 months after COPD diagnosis, as more patients compared to baseline were prescribed additional maintenance therapy in the 24-month period. A high proportion of patients were switched or discontinued from their index treatment within 24 the months of diagnosis. Patients starting on LAMA or LABA+ICS therapy were most likely to change to triple therapy. Thus, the results suggest that COPD treatment evolution is progressive and patients likely need more than one maintenance medication to provide symptom relief and/or prevent exacerbations. The changes in therapy observed in this real world cohort suggest that it is difficult to achieve a consistently improved COPD disease state over two years and the unmet need remains.

**Acknowledgments**

All listed authors met the criteria for authorship set forth by the International Committee for Medical Journal Editors. Editorial support, in the form of development, assembling tables and figures, collating author comments, copyediting, fact checking, and referencing, was performed by Anirudha Chillar of Cactus Communications Inc.

**Author Contributions**

Conceived and designed the experiments: KW YP. Performed the experiments: AS KW. Analyzed the data: AS KW. Contributed reagents/materials/analysis tools: AS. Wrote the paper: KW YP.

**References**

1. GOLD strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available: http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf. Accessed 2014 Jun 1.
2. National Institute for Health and Clinical Excellence. NICE clinical guideline 101. Available: http://www.nice.org.uk/nicemedia/live/13029/49397/49397.pdf. Accessed 2013 Jul 26.
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532–555.
4. Bellamy D, Bouchard J, Henrichsen S, Johansson G, Langhammer A, et al. (2006) International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 15: 48–57.
5. Martin J, Garrizo S, Gascon M, Sanchez A, Gallego B, et al. (2001) Inspiratory Capacity, Dynamic Hyperinflation, Breathlessness, and Exercise Performance during the 6-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 163: 1395–1399.
6. Wedzicha J, Decramer M, Seemungal T (2012) The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 40: 1545–1554.
7. van der Molen T, Cazzola M (2012) Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 21: 101–108.
8. American Thoracic Society/European Respiratory Society. Standards for diagnosis and management of patients with COPD. Available: http://www.thoracic.org/clinical/copd-guidelines/resources/copddoc.pdf. Accessed 2013 Nov 22.
9. Othoff M, Jenkins C, Leuppi JD (2013) Chronic obstructive pulmonary disease - a treatable disease. Swiss Med Wkly 143:0.
10. Salinas GD, Williamson JC, Kaltham R, Thomashow B, Scheckermann J, et al. (2011) Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis 6: 171–179.
11. Jochmann A, Neubauer F, Miedinger D, Schafroth S, Tamm M, et al. (2010) General practitioner’s adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly; April 21.
12. Perez X, Wisnivesky JP, Lurslurchachai L, Kleinman LC, Kronish IM (2012) Barriers to adherence to COPD guidelines among primary care providers. Respir Med 106: 374–381.
13. Clinical Practice Research Datalink. Available: http://www.cprd.com/home/. Accessed 2012 Oct 15.
14. Khan NF, Perera R, Harper S, Rose PW (2010) Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 11:1.
15. Cramer JA, Bradley-Kennedy C, Scaleria A (2007) Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J 14: 25–29.
16. Hassey A, Gerrett D, Wilson A (2001) A survey of validity and utility of electronic patient records in a general practice. BMJ 322: 1401–1405.